SitagliptinThird Party Manufacturing in India

Sitagliptin works by slowing the inactivation of incretin hormones, which play a crucial role in glucose homeostasis.

It selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), preventing the rapid degradation of hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By maintaining elevated levels of these active incretins, Sitagliptin stimulates the pancreas to increase insulin secretion in a glucose-dependent manner while suppressing the release of glucagon.

Unlike medications that directly stimulate insulin release regardless of glucose levels, Sitagliptin has a very low risk of causing hypoglycemia. It is highly effective and well-tolerated for adults with type 2 diabetes mellitus, providing consistent postprandial and fasting blood glucose control.

Therapeutic Uses

Sitagliptin is prescribed for the treatment of:

• Type 2 Diabetes Mellitus: Used as an adjunct to diet and exercise to improve glycemic control in adult patients.
• Combination Therapy: Widely prescribed alongside Metformin, sulfonylureas, or insulin to achieve target blood glucose levels in patients requiring advanced management.

Why Manufacturers Choose Sitagliptin

As a modern, highly effective DPP-4 inhibitor, Sitagliptin is a premium offering in the antidiabetic segment. Its low risk of hypoglycemia and weight-neutral profile make it a top choice for physicians, driving significant market growth.

This makes Sitagliptin one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies looking to provide advanced diabetes care solutions.